Teva and Alvotech get FDA review acceptance for its proposed biosimilar to Eylea

Alvotech (NASDAQ:ALVO) and Teva Pharmaceuticals (NYSE:TEVA) said on Tuesday that the U.S. FDA has accepted for review a Biologics License Application for a biosimilar targeting Regeneron’s (REGN) blockbuster eye disease therapy, Eylea.

A biologic named AVT06, Teva (NYSE:TEVA), and